PTC Therapeutics, Inc.
PTCTHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, PTC Therapeutics, Inc. focuses on Biotechnology services and products. PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States. The company carries a $5.66B market cap, placing it firmly in the mid-cap category. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Market Cap
$5.66B
Beta
0.53
P/E (TTM)
—
P/E (Fwd)
24.51
EPS (TTM)
$-2.54
EPS (Fwd)
$2.78
ROE
—
ROA
-1.5%
Cash
$1.89B
Total Debt
$2.72B
Free CF
-$418.1M
52W Change
33.4%
Annual Financials
Cash vs Debt
The company holds $1.89B in cash, though total debt stands at $2.72B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$418.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $698.8M (2022) to $1.73B (2025), reflecting a 148% increase over the period.
PTCT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for PTC Therapeutics, Inc. and its sector.